|
Delayed
Toronto S.E.
13:27:49 2026-10-15 EDT
|
5-day change | 1st Jan Change | ||
| 0.3950 CAD | 0.00% |
|
-16.84% | +5.33% |
| 09-28 | Diagnos Inc. Submits Section 513(G) Request for Information to U.S. Food and Drug Administration for Cara System | CI |
| 09-28 | DIAGNOS Submits Request for Information to US FDA for CARA System | MT |
Company Valuation: DIAGNOS Inc.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 35.98 | 17.37 | 24.36 | 17.84 | 30.56 | 33.11 |
| Change | - | -51.72% | 40.26% | -26.75% | 71.25% | 8.36% |
| Enterprise Value (EV) 1 | 35.09 | 17.63 | 26.37 | 20.81 | 30.4 | 32.59 |
| Change | - | -49.75% | 49.55% | -21.08% | 46.05% | 7.22% |
| P/E | -16.6x | -6.59x | -9.68x | -5.48x | -6.18x | -6.51x |
| PBR | 32.1x | -153x | -12.5x | -5.9x | 131x | 48.2x |
| PEG | - | -0.4x | 1.59x | -0.3x | -0.5x | 0.5x |
| Capitalization / Revenue | 135x | 39.6x | 50.2x | 105x | 294x | 506x |
| EV / Revenue | 131x | 40.2x | 54.3x | 122x | 293x | 498x |
| EV / EBITDA | -15.7x | -6.71x | -12x | -8.06x | -7.99x | -7.67x |
| EV / EBIT | -15.4x | -6.63x | -11.8x | -7.98x | -7.95x | -7.64x |
| EV / FCF | -41.8x | -14.6x | -21.6x | -13.7x | -11.7x | -13.2x |
| FCF Yield | -2.39% | -6.84% | -4.63% | -7.32% | -8.55% | -7.57% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0325 | -0.0379 | -0.0356 | -0.0429 | -0.0486 | -0.0422 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.2671 | 0.4388 | 0.4857 | 0.1702 | 0.1038 | 0.0655 |
| EBITDA 1 | -2.239 | -2.626 | -2.203 | -2.583 | -3.806 | -4.25 |
| EBIT 1 | -2.283 | -2.66 | -2.237 | -2.607 | -3.824 | -4.263 |
| Net income 1 | -2.051 | -2.608 | -2.481 | -3.121 | -4.286 | -4.555 |
| Net Debt 1 | -0.8904 | 0.2635 | 2.008 | 2.967 | -0.1637 | -0.5251 |
| Reference price 2 | 0.5400 | 0.2500 | 0.3450 | 0.2350 | 0.3000 | 0.2750 |
| Nbr of stocks (in thousands) | 66,626 | 69,474 | 70,611 | 75,934 | 101,863 | 120,413 |
| Announcement Date | 6/8/21 | 7/13/22 | 7/13/23 | 7/17/24 | 5/28/25 | 6/11/26 |
1CAD in Million2CAD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 34.44M | |
| 22.43x | 3.67x | 12.81x | 2.97% | 215B | |
| 22.58x | 4.75x | 11.66x | 0.73% | 194B | |
| 15.97x | 1.74x | 9.13x | 3% | 128B | |
| -131.83x | 18.31x | 100.67x | -.--% | 118B | |
| -559.51x | 39.76x | 163.36x | -.--% | 115B | |
| 15.03x | 2.7x | 10.41x | 5.36% | 87.63B | |
| 21.53x | 5.62x | 13.79x | 2.63% | 63.48B | |
| 23.9x | 1.98x | 12.56x | 1.3% | 46.63B | |
| 14.23x | 2.07x | 8.78x | 5.47% | 46.31B | |
| Average | -61.74x | 8.95x | 38.13x | 2.39% | 101.47B | |
| Weighted average by Cap. | -63.55x | 9.33x | 39.14x | 2.08% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ADK Stock
- Valuation DIAGNOS Inc.
Select your edition
All financial news and data tailored to specific country editions
